title: Comment: Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents.
authors.affiliation: PhD Candidate in Health Policy, Harvard University, Fellow in Pharmaceutical Policy Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, lfaden@fas.harvard.edu.
authors.forename: Laura
authors.initials: L
authors.lastname: Faden
authors.affiliation: Professor of Population Medicine, Director of the Drug Policy Research Group, Harvard Medical School and Harvard Pilgrim Health Care Institute.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Soumerai
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D017723:Drug Utilization Review / Q000331:legislation & jurisprudence*; D005260:Female; D006078:Government Programs; D006296:Health Services / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D015397:Program Evaluation; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents